Sign in

Trial result ·

Defining a Clinically Meaningful Within-Person Change Threshold for the Psychomotor Vigilance Test in Narcolepsy Type 1.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

Researchers looked at a test of attention in people with narcolepsy type 1. The test counts lapses, when a person reacts slower than 500 ms. They wanted to know how big a drop in lapses really matters to patients. They used data from 2 late-stage trials. Both trials compared the drug oveporexton with a dummy drug (placebo). One trial had 166 people and the other had 105. People also rated how much they felt they had changed.

What they found

People who said they felt better had fewer lapses on the test. The more they felt better, the fewer lapses they had. A drop of at least 2 lapses was judged a real gain in attention. Other checks backed up this cut-off. At day 84, more people on oveporexton than on placebo reached this level. This held in both trials.

What it means for patients

The authors say oveporexton gave gains in attention that matter to patients. A drop of 2 or more lapses was more likely with the drug than placebo. The study also gives a cut-off for a real change on this test.

Why it is not certain yet

The abstract covers only people with narcolepsy type 1. The results come from 2 trials of one drug. One check was done after the fact, not planned ahead. The abstract does not give side effects. It also gives no results past day 84.

Source

Defining a Clinically Meaningful Within-Person Change Threshold for the Psychomotor Vigilance Test in Narcolepsy Type 1.

PubMed · PMID 42573945

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Narcolepsy publications